- Home
- MTEX vs SNTI Comparison
MTEX vs SNTI Comparison
Compare MTEX & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEX
- SNTI
- Stock Information
- Founded
- MTEX 1993
- SNTI 2016
- Country
- MTEX United States
- SNTI United States
- Employees
- MTEX N/A
- SNTI N/A
- Industry
- MTEX Medicinal Chemicals and Botanical Products
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- MTEX Health Care
- SNTI Health Care
- Exchange
- MTEX Nasdaq
- SNTI Nasdaq
- Market Cap
- MTEX 20.0M
- SNTI 85.3M
- IPO Year
- MTEX 1999
- SNTI N/A
- Fundamental
- Price
- MTEX $9.20
- SNTI $2.26
- Analyst Decision
- MTEX
- SNTI Strong Buy
- Analyst Count
- MTEX 0
- SNTI 2
- Target Price
- MTEX N/A
- SNTI $8.50
- AVG Volume (30 Days)
- MTEX 18.7K
- SNTI 381.5K
- Earning Date
- MTEX 08-12-2025
- SNTI 08-12-2025
- Dividend Yield
- MTEX N/A
- SNTI N/A
- EPS Growth
- MTEX N/A
- SNTI N/A
- EPS
- MTEX N/A
- SNTI N/A
- Revenue
- MTEX $115,036,000.00
- SNTI N/A
- Revenue This Year
- MTEX N/A
- SNTI N/A
- Revenue Next Year
- MTEX N/A
- SNTI $150.00
- P/E Ratio
- MTEX N/A
- SNTI N/A
- Revenue Growth
- MTEX N/A
- SNTI N/A
- 52 Week Low
- MTEX $6.75
- SNTI $1.52
- 52 Week High
- MTEX $16.49
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- MTEX 45.15
- SNTI 40.57
- Support Level
- MTEX $8.81
- SNTI $2.05
- Resistance Level
- MTEX $10.23
- SNTI $2.35
- Average True Range (ATR)
- MTEX 0.68
- SNTI 0.29
- MACD
- MTEX -0.02
- SNTI 0.01
- Stochastic Oscillator
- MTEX 32.90
- SNTI 25.33
About MTEX Mannatech Incorporated
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.